By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RedHill Biopharma Ltd. 

21 Ha’arba’a Street

Tel-Aviv    64739  Israel
Phone: 972-0-3-541-3131 Fax: 972-0-3-541-3144



Company News
RedHill Biopharma (RDHL) Reports 2017 First Quarter Financial Results 5/3/2017 7:43:19 AM
RedHill Biopharma (RDHL) To Host First Quarter 2017 Financial Results Conference Call On May 3, 2017 4/25/2017 10:10:33 AM
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In The BEKINDA Phase II Study For IBS-D 4/24/2017 11:27:18 AM
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Of The Positive YELIVA Phase I Study Results In Advanced Solid Tumors 4/20/2017 8:36:38 AM
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017 8:28:55 AM
RedHill Biopharma (RDHL) Receives Notice Of Allowance For Two Additional U.S. Patents Covering BEKINDA 4/18/2017 10:41:56 AM
RedHill Biopharma (RDHL) And IntelGenx Corp. Announce Marketing Approval Of RIZAPORT For Migraines In Luxembourg 4/13/2017 9:48:55 AM
RedHill Biopharma (RDHL) Announces Exclusive U.S. License From Entera Health For Commercial GI Product Enteragam 4/5/2017 12:56:49 PM
RedHill Biopharma (RDHL) Receives FDA Orphan Drug Designation For YELIVA For The Treatment Of Cholangiocarcinoma 4/4/2017 11:39:21 AM
RedHill Biopharma (RDHL) Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn’s Disease 3/21/2017 10:50:49 AM